NICE appraisals should be everybody's business
Authors:
Abstract
When Newbury and Community Primary Care Trust appealed against NICE9s decision on Herceptin, it was the first to do so. Jane Wells and Claire Cheong-Leen explain the process and why other trusts should make their voices heard in appraisals of new treatmentsKeywords
This publication has 5 references indexed in Scilit:
- New treatments for neovascular acute macular degenerationBMJ, 2007
- How much will Herceptin really cost?BMJ, 2006
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerNew England Journal of Medicine, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005